series-b
Stage
2
Investors
About
Alume Biosciences develops a nerve illumination technology using a fluorescent compound to help surgeons visualize and preserve nerves during surgery, currently conducting Phase 3 clinical trials for their lead product bevonescein (ALM-488).
Explore Alume Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.